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We report on a case of a patient with HIV infection, diagnosed 18 months prior to the development
of an anti-glomerular basement membrane (anti-GBM) rapidly progressive glomerulonephritis; this
is probably the first report of such an association. A 30-year-old white man presented with elevation
of serum creatinine (1.3 - 13.5 mg/dL within one month). At admission, the urinalysis showed proteinuria
of 7.2 g/L and 8,000,000 erythrocytes/mL. Renal biopsy corresponded to a crescentic diffuse proliferative
glomerulonephritis mediated by anti-GBM, and serum testing for anti-GBM antibodies was positive;
antinuclear antibodies (ANA) and anti-neutrophilic cytoplasmic antibodies (ANCA) were also positive.
The patient underwent hemodyalisis and was treated with plasmapheresis, cyclophosphamide and
prednisone. The association described here is not casual, as crescentic glomerulonephritis is not
common in HIV-positive patients, anti-GBM glomerulonephritis is rare and anti-GBM antibodies
are frequently observed in HIV-positive subjects when compared to the overall population. Based on
the current case and on the elevated frequency of the positivity for such antibodies in this group of
patients, it is advisable to be aware of the eventual association between these two conditions and to
promote an active search for anti-GBM antibodies and early diagnosis of eventual urinary abnormalities
in HIV-positive subjects, considering the severity of anti-GBM glomerulonephritis.
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Goodpasture’s syndrome includes glomerulonephritis,
lung hemorrhage and glomerular basement membrane
antibodies (GBM) [1]. Lung hemorrhage occurs in 50 to 70%
of the cases, with greater incidence in smokers. It may be
determined or exacerbated by pulmonary infection or
hypervolemia and can also occur in the absence of significant
renal disease [2,3]. From an epidemiological point of view,
HLA-DR15 seems to be the most important risk factor for the
development of this disease.  HLA-DR7 has also been related
to the process, but it is considered to be less involved [4].
In the case of renal involvement, antibodies are strongly
linked to the GBM in a linear pattern, and sometimes weakly
to the Bowman’s capsule and to the tubular basement
membrane, as demonstrated by immunofluorescence. This
technique is probably sensitive enough for identification of
the antibodies, but it is not totally specific, as the linear pattern
has already been demonstrated in kidney allografts, diabetes
mellitus, systemic lupus erithematosus, fibrillary
glomerulonephritis, and even in normal kidneys [2]. In addition,
circulating anti-GBM autoantibodies can be demonstrated by
several other available assays with different sensitivities and
specificities [2,3].
Lung hemorrhage is not a constant finding, both in patients
and in experimental animal models, and it has a weak correlation
with the serum levels of anti-GBM antibodies. Initially, it was
thought that the pulmonary and the renal antigens were
distinct. Recently, it has been demonstrated that the antigen
is the same in both tissues. However, the accessibility of the
antibody to the antigen is different in the two tissues. While
a highly specific antibody to the basement membrane will link
to the GBM after an intravenous injection, probably due to
the fenestrated nature of the glomerular endothelium, there
should be previous insult in the alveolus that exposes the
antigen epitopes in order to allow binding to circulating
antibodies. Therefore, there seems to be an association
between toxicity by oxygen, smoking, organic solvents,
infection and the development of lung hemorrhage [5,6].
Recently, it has been suggested that the exposition of the
antigen by tissue injury might be the main pathogenic
mechanism [7].
We report on a case of a patient with HIV infection,
diagnosed 18 months prior to the development of an anti-
GBM rapidly progressive glomerulonephritis. To the best of
our knowledge, this is the first report of such an association.
Case Report
A 30-year-old white man presented with a history of acute
hepatitis B virus 18 months previously, when the diagnosis of
HIV infection was also established and a year previously,
secondary syphilis was diagnosed. At hospitalization, he
presented with nephritic syndrome and acute renal failure.
The serum creatinine increased from 1.3 to 13.5 mg/dL in one
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month. At admission, the initial urinalysis showed proteinuria
of 7.2 g/L and 8,000,000 erythrocytes/mL, with evident
erythrocytic dismorfism and 30,000 leukocytes/mL. The
patient had clinical and serological criteria of cured hepatitis
B (negative HbsAg, positive anti-HBc IgG, negative HbeAg,
positive anti-HBs) and for syphilis (positive VDRL 1/4 -
decreasing titre, positive FTA-Abs). His initial blood count
revealed hemoglobin 13.9g/dL, hematocrit 40%, leukocytes
7,100/mL, platelets 260,000/mL; a chest X-ray was normal; the
physical examination revealed no alteration and his blood
pressure was 120 x 80 mmHg. Ultrasonography showed both
kidneys of normal size. He was submitted to a renal biopsy.
Light microscopy showed eight glomeruli with focal fibrinoid
necrosis, substantial endocapillary hypercellularity, a
moderate degree of neutrophilic infiltration and circumferential
cellular crescents in 50% of the sampled glomeruli; the intact
capillary walls had normal thickness (Figure 1-3); in addition,
there was moderate tubular acute necrosis; the
immunofluorescence technique revealed linear fluorescent
deposits of IgG and C3 along the GBM. In summary, the renal
biopsy corresponded to a progressive diffuse proliferative
glomerulonephritis mediated by anti-GBM. Serum testing for
anti-GBM antibodies was positive, with a titer of 68 U/mL;
serum tests for ANA and ANCA were positive; total
complement activity was 160 UCH50/mL (reference value: 130
to 330), C2 98% (RV: > 70%), C3 116 mg/dL (RV: 90 to 180), C4
27 mg/dL (RV: 10 to 40), negative for anti-dsDNA, -RNP, -Sm,
-Ro and -La, undetectable HIV viral load and CD
4
 495/mL (RV
> 1,000). The patient underwent hemodyalisis and was treated
with 14 sessions of plasmapheresis, a low dose of
cyclophosphamide (1.5 mg/kg) and prednisone (1 mg/kg) for
two weeks. The treatment was discontinued due to the
persistence of signs and symptoms and development of
leukopenia. The patient was maintained in dialysis and did
not present any infectious complications or pulmonary
symptomatology within a six-month follow-up period.
Discussion
HIV-positive patients may present with renal involvement
related to the infection itself, to supervening infections or to
the side effect of drugs used in treatment [8,9].
Several glomerulopathies have been observed in HIV-
positive patients, such as IgA nephropathy, membranous
glomerulonephritis, proliferative glomerulonephritis, minimal
change disease, and particularly the collapsing variant of focal
segmental glomerulosclerosis, which is an usual presentation
of HIV-associated  nephropathy [10-14].
We present a case of anti-GBM rapidly progressive
glomerulonephritis in an HIV positive patient, an association
that, to the best of our knowledge, has not been previously
reported.
For treatment, considering the severity of the renal failure,
we decided to use the same immunosuppressive regimen
recommended for patients with anti-GBM glomerulonephritis,
as the viral load of the patient was undetectable and he did
not present with other active or recent infections that would
contraindicate such a procedure. This treatment is based on
the premise that the autoantibodies are responsible for the
tissular lesion, and the aim is their removal and blockage of
their synthesis. Plasmapheresis (4L/day during 14 days)
concomitant to the administration of cyclophosphamide (2-3
mg/kg/day) and prednisone (1 mg/kg/day) for three months
has been successfully used [2,3,15]. Post-treatment relapse is
rare, and in some cases has been related to smoking. In non-
treated cases, antibody titers can be detected in the blood for
up to one year or more [3]. For those patients progressing to
irreversible renal failure, renal transplantation can be
performed safely after the antibodies are no longer detectable
in the blood. Some researchers consider it wise to wait at least
six months after the first post-therapy negative result or at
least two years for non-treated patients [3].
When the treatment is initiated with serum creatinine
inferior to 600 µmol/L (6.7 mg/dL), 80% to 90% of the patients
are maintained without the need for dialysis after one year.
When treatment is initiated with the patients already in dialysis
or with serum creatinine superior to 600µmol/L, this percentage
falls to 0% to 18% [2]. Alternatively, immunoadsorption with
protein A has been used in substitution for plasmapheresis
[16,17]. Also, mycophenolate mofetil was administered with
success to one patient with frequent relapses of lung
hemorrhage, utilizing the normal dosage [18].
In our patient, there was no evidence of a short-term
response, and as the patient developed leukopenia with the
use of cyclophosphamide, after conclusion of the conventional
initial treatment, the immunosuppressive drugs were
discontinued.
The most intriguing aspect of this case report is the
association between anti-GBM glomerulonephritis and HIV
infection. Currently, there is sufficient evidence that HIV is
etiopathogenetically involved in several autoimmune
phenomena [19]. Antibodies against platelets and white blood
cells have been demonstrated in patients with AIDS [20]. It
has also been demonstrated that T-cells infected by HIV may
expose previously occult CD
4
 epitopes, leading to
downregulation of the CD
4
 molecules, mediated by monoclonal
antibodies against CD
4
 or gp-120 [21]; in addition, there is
evidence that an autoimmune  response mediated by T-cells
is involved in the pathophysiology of HIV infection [21], and
that it is likely that IL-6 and IL-10 are involved in the
development of malignancy and autoimmunity in AIDS [22].
The association between membranous nephropathy and
vasculitis with anti-GBM antibodies favors the hypothesis
that GBM damage in these diseases can trigger an autoimmune
response against GBM [2]. This hypothesis is also further
corroborated by two case reports that describe patients who
developed Goodpasture’s syndrome after lithotripsy [23,24].
There is also an epidemiological association between exposure
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to organic solvents and progressive glomerulonephritis, with
the eventual development of Goodpasture’s syndrome [2].
The antigen involved is the α3 chain of type IV collagen, the
main structural component of the glomerular basement
membrane. The antigenic region of the molecule is the 230
amino acid non-collagen domain called NC1, in the carboxyl
terminal region [1,2,25].
Calderon et al. [1] detected anti-GBM antibodies, with
evidence of anti-GBM glomerulonephritis, in HIV-negative
patients with Pneumocystis carinii lung infection, and not in
HIV-negative patients who carried the pathogen but did not
have pneumonia, which suggested that the alveolar lesion
caused by the agent is responsible for the development of the
autoimmune disease. Moreover, HIV-positive patients with P.
carinii pneumonia did not present anti-GBM antibodies.
On the other hand, Savige et al. [26] found anti-GBM
antibodies in 17% of HIV-positive patients, with a significant
correlation between the presence of the antibody and CD
4
counts lower than 400/mL. Also, antinuclear antibodies were
found in 23% and ANCA in 17% of the HIV-positive subjects.
There was no correlation between the presence of antibodies
and the development of autoimmune disease. Even with
moderate and elevated titers of anti-GBM antibodies in one of
the cases, there was no clinical or laboratory evidence of
glomerular disease. It is noteworthy that even normal
individuals may have increased serum levels of some
autoantibodies with no manifestation of disease [27-29].
Our report yields the hypothesis that the immune response
in HIV patients may be etiopathogenetically involved in the
development of anti-GBM glomerulonephritis. Some findings
reinforce the idea that the association described in this case
is not casual, such as: crescentic glomerulonephritis is not
common in HIV-positive patients [26], anti-GBM
glomerulonephritis is rare and anti-GBM antibodies are
frequently observed in  HIV-positive subjects when compared
to the overall population [26].
We conclude that HIV-positive subjects with anti-GBM
antibodies deserve special attention concerning the early
diagnosis of eventual urinary abnormalities, considering the
severity of anti-GBM glomerulonephritis. It is intriguing that
anti-GBM glomerulonephritis has not been reported more
frequently in HIV-patients, due to the number of these
patients with anti-GBM antibodies in their serum and that
these antibodies have a recognized pathogenetic role in such
glomerulonephritis [26]. Based on our case report and on
the elevated frequency of positivity for such antibodies in
this group of patients, it is advisable to be aware of a possible
association between these two conditions and to promote
an active search for anti-GBM antibodies in HIV-positive
subjects.
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